News

August 8, 2024—(BRONX NY)—A discovery by a three-member Albert Einstein College of Medicine research team may boost the effectiveness of stem-cell transplants, commonly used for patients with cancer, blood disorders, or autoimmune diseases caused by defective stem cells, which produce all the body’s different blood

A scientist at VCU Massey Comprehensive Cancer Center was awarded more than $2.7 million in grant funding to evaluate the effectiveness of a new targeted drug in treating the most common type of lung cancer. Credit: VCU Massey Comprehensive Cancer Center A scientist at VCU

A new study reviews how cancer-associated fibroblasts (CAFs) influence lymph node metastasis. Researchers identified various CAF subsets that interact with the tumor microenvironment, promoting cancer spread. By targeting these specific subsets, new therapeutic strategies can be developed to inhibit metastasis, potentially improving patient outcomes. This

Progenitor exhausted CD8+ T (Tpex) cells have emerged as a pivotal component in tumor immunotherapy due to their unique ability to self-renew and rapidly proliferate. These cells have shown promise in expanding and differentiating into functional exhausted CD8+ T cells, significantly enhancing clinical outcomes. Understanding

“These findings indicate that renalase-1 is a potential antigen for TCR recognition in melanoma and could be considered as a target for immunotherapy.” Credit: 2024 Zaman et al. “These findings indicate that renalase-1 is a potential antigen for TCR recognition in melanoma and could be

LOS ANGELES — A study from the USC Head and Neck Center, part of Keck Medicine of USC and the USC Caruso Department of Otolaryngology – Head and Neck Surgery, suggests that cannabis, the most commonly used illicit substance worldwide, is associated with an increased occurrence of

A research team led by Professor Ying Wai CHAN from the School of Biological Sciences at The University of Hong Kong (HKU) has made a significant breakthrough in understanding how cancer cells develop resistance to a class of cancer drugs known as PARP inhibitors. Their

CAMBRIDGE, Mass., Aug 8, 2024 — Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced ISM6331, potential best-in-class pan-TEAD inhibitor, has received the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for the treatment of mesothelioma, following the

Using zebrafish “Avatars”, an animal model developed by the Cancer Development and Innate Immune Evasion lab at the Champalimaud Foundation (CF), led by Rita Fior, Mayra Martínez-López – a former PhD student at the lab now working at the Universidad de las Américas in Quito,

BUFFALO, NY – August 7, 2024 – A new editorial paper was published in Oncotarget’s Volume 15 on July 12, 2024, entitled, “How to deal with runaway metastatic disease?” In this new editorial, Justine Paris and Guilhem Bousquet from Université Paris Cité, Université Sorbonne Paris